All In Biotech

Drug Trial Radar · NCT07652814

Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years

An Open Label, Single Center, Exploratory Study of the Safety and Efficacy of Avalglucosidase Alfa Patients With Non-classic Pompe Disease Aged ≥ 5 Years

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Oct 13, 2022

Primary completion

Mar 9, 2028

Study completion Mar 9, 2028

Sponsor

Lead sponsor
Iris PlugAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to study the efficacy and safety of treatment with avalglucosidase alfa in patients with late onset Pompe disease that previously deteriorated on alglucosidase alfa. The main question it aims to answer is: * Is switching to avalglucosidase alfa in late-onset Pompe patients deteriorating on alglucosidase alfa safe? * Is switching to avalglucosidase alfa in late-onset Pompe patients deteriorating on alglucosidase alfa potentially more effective? Participants will switch to biweekly avalglucosidase alfa infusions (instead of alglucosidase alfa infusions) and perform assessment for: * Efficacy: muscle strength and function, pulmonary function, patient-reported outcomes. * Safety: Adverse events assessment, physical examination, clinical laboratory evaluations, vital signs, ECGs and immunogenicity assessments. * Pharmacokinetic assessments during 2 avalglucosidase alfa infusions.

Conditions

  • Glycogen Storage Disease Type II Late Onset
  • Pompe Disease (Late-onset)
  • Pompe Disease Late-Onset
  • Pompe's Disease Juvenile Onset
  • Pompe Disease

Interventions

  • Avalglucosidase AlfaDrug

    Enzyme replacement therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence/occurrence of adverse eventsTime frame: From enrollment to the end of study duration at 5 years
  2. The occurence of antibodies against avalglucosidase alfaTime frame: From enrollment to the end of study duration at 5 years
  3. Clinical laboratory evaluations aimed at liver and muscle function.Time frame: From enrollment to the end of study duration at 5 years
  4. Changes in muscle strength using manual muscle testing (MMT)Time frame: From enrollment to the end of study duration at 5 years
  5. Changes in muscle strength using hand-held dynamometry (HHD)Time frame: From enrollment to the end of study duration at 5 years
  6. Changes in muscle function using Quick Motor Function Test (QMFT)Time frame: From enrollment to the end of study duration at 5 years
  7. Changes in muscle function using the 6-Minute Walk Test (6-MWT)Time frame: From enrollment to the end of study duration at 5 years
  8. Changes in muscle function using timed testsTime frame: From enrollment to the end of study duration at 5 years
  9. Changes in pulmonary function using forced vital capacity (FVC)Time frame: From enrollment to the end of study duration at 5 years
  10. Changes in pulmonary function using Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP)Time frame: From enrollment to the end of study duration at 5 years
  11. Changes in patient reported outcome (PRO) measures using the Rasch-built Pompe-specific Activity scale (R-PAct)Time frame: From enrollment to the end of study duration at 5 years
  12. Changes in patient reported outcome (PRO) measures using the 36-Item Short Form Health Survey (SF-36)Time frame: From enrollment to the end of study duration at 5 years
  13. Changes in patient reported outcome (PRO) measures using the TNO-AZL Child Quality of Life Questionnaire)Time frame: From enrollment to the end of study duration at 5 years
  14. Changes in patient reported outcome (PRO) measures using the modified Borg scaleTime frame: From enrollment to the end of study duration at 5 years
  15. Pharmacokinetics of avalglucocidase alfaTime frame: From enrollment up to 1 year of study duration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Erasmus MC

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.